Abcam board of directors
|
|
Michael Redmond, who joined Abcam in February 2009, has substantial international experience in the pharmaceutical industry gained in both executive and non-executive capacities at businesses ranging from multinational organisations to start-up companies. He is currently chairman of Dechra Pharmaceuticals plc and his recent chairmanships include Synexus Clinical Research plc, Arakis Ltd and Microscience Ltd. His executive career began at Glaxo Group plc in 1967 and he has held senior executive positions in marketing and management at companies including Schering Plough Corporation and Fisons plc. He took over as Chairman of the company in November 2009. |
|
|
Jonathan Milner is a highly experienced entrepreneur and business leader with a background in genetic research. He gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath University. From 1992 to 1995 he was a research fellow for Pfizer Pharmaceuticals at Bath University, following which he was a research fellow at Cambridge University in the laboratory of Professor Tony Kouzarides, studying genes and proteins associated with human cancers. Whilst working in research he identified the potential market opportunity in supplying high quality antibodies to support protein interaction studies. He founded Abcam, with David Cleevely and Prof Tony Kouzarides, in February 1998 as an internet-based business to supply this rapidly growing market. He is an active member of the Cambridge business community and is Chairman of Cambridge Temperature Concepts Ltd, a privately held medical device company developing a reliable system for ovulation monitoring. |
|
|
Jim Warwick has an MA in Computer Science from the University of Cambridge. From 1986 to 2003 he worked for Analysys Ltd, a Cambridge-based telecommunications consultancy, heading up the IT, software and web development initiatives. During this period he also held a number of non-executive directorships with external organisations, including VBN Ltd, a web-based hosting company specialising in business cluster and innovation network solutions. Jim joined Abcam in 2001 as Technical Director, focussing on the development of the website and the systems integral to support it, and took over operational management of the UK office as Managing Director in June 2004. In this capacity he worked on both cost-saving and efficiency improvement projects, including the bar-coding and automation of inventory handling within the Group. Jim is responsible for building infrastructure on a scalable basis, and he has overseen the strategy and implementation of Abcam’s overseas office expansion in Japan, which has been instrumental in delivering improved volumes and margins to the business. In 2009, Jim took on the role of Chief Operating Officer, with operational responsibility for the Group as a whole. |
|
|
Jeff Iliffe is a qualified accountant who was appointed as Abcam’s Chief Finance Officer in November 2007, having previously worked for the Company as a financial consultant. He has extensive relevant experience of the City, industry and internet-based business. Mr Iliffe was a corporate financier in life sciences at Panmure Gordon & Co between 1989 and 1996. He then moved into industry, holding a number of financial positions at companies including the environmental consultancy Enviros Group Ltd and the biotechnology company Plethora Solutions plc. Prior to joining Abcam, he was chief financial officer at the e-commerce company St Minver Ltd. |
|
|
Mark Webster is an experienced pharmaceutical marketeer who joined the Abcam Board as a non-executive Director in July 2006. He is a Chemistry graduate from Durham University who has worked at a number of international pharmaceutical companies including Abbott Laboratories, Shire Pharmaceuticals, Bayer and ProStrakan, where as Head of Global Marketing and North America he was responsible for setting up ProStraken's US business. At Bayer he held the position of Senior Vice President, Head of Global Strategic Marketing and Licensing/Acquisitions and was a member of Bayer Pharmaceutical’s Management Committee. As Vice President of Anti-Virals, US Pharmaceuticals for Abbott he launched the HIV drug Kaletra, which generated more than $1 billion in revenue. |
|
|
Tony Kouzarides is a co-founder of Abcam and has played a key role in expanding Abcam's antibody product range into the chromatin research area. Prof Kouzarides holds the Royal Society Napier Professorship in Cancer Biology at the University of Cambridge, UK, where he leads a laboratory that investigates the basic cellular role of chromatin-modifying enzymes and their role in human cancer. He is a co-founder of Chroma Therapeutics, which identifies drugs against cancer, and is the founder and director of cancer charity Conquer Cancer, operating in Spain. |
|
|
Peter Keen is a chartered accountant with more than 24 years’ experience in the financing and management of biotechnology companies. He joined Abcam’s Board in October 2005, prior to the Company’s IPO. He is currently corporate development and finance director of the private biotechnology company Serentis Ltd and a non-executive director of Ark Therapeutics plc and of The Biotech Growth Trust plc. Mr Keen has a notable track record in the UK biotechnology sector. He was co-founder and finance director of Chiroscience Group plc after which he helped establish Merlin Biosciences, where he was responsible for a number of investments including Ark Therapeutics, Cyclacel, ReNeuron and Vectura. More recently, he was chief financial officer of Arakis, until its successful trade sale in 2005, and a partner with the technology venture firm DFJ Esprit. |
|
|
Tim Dye is a former Chief Executive of William Ransom & Son plc, a position he held until January 2008. Through a series of acquisitions, he led the transformation of William Ransom into one of the UK’s largest natural healthcare groups. Prior to joining Ransom in 1999, and following an early career as a strategy consultant, he founded and ran businesses in automated meter reading, environmental management and property development. He has an MA in Economics from Cambridge University. |
